ChineoMedical Technology

ChineoMedical Technology is a clinical-stage biotechnology company focused on developing next-generation cell therapies for solid tumors. Based in Beijing, China, the company specializes in 'Super-charging' Tumor Infiltrating Lymphocyte (ScTIL) technology, which utilizes genetic modification to enhance the expansion and anti-tumor efficacy of T cells within the immunosuppressive tumor microenvironment. ChineoMedical also develops hybrid CAR-T and TCR-T therapies, as well as a machine learning-driven platform for the rapid identification of neoantigen-reactive T cells. Their pipeline targets a variety of advanced malignancies, including gastrointestinal and urogenital cancers, using antigens such as CD19, NY-ESO-1, and PD-L1. The company's goal is to provide personalized and potent immunotherapy solutions for patients with difficult-to-treat solid cancers.